Skip to main content

3 Result(s)

within Hui-qi Dai Remove this filter

and

  1. Article

    Open Access

    Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy

    Transarterial chemoembolization (TACE) is the first-line treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). It is of high clinical significance to explore the synergistic effect of T...

    **g Zhou, Ji Feng, Yong Wu, Hui-Qi Dai, Guang-Zhi Zhu… in Experimental & Molecular Medicine (2022)

    Download PDF (7663 KB) View Article

  2. No Access

    Article

    Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

    Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it can only extend limited survival. It is imperative to find a combination strategy to increase sorafenib efficacy. Arte...

    Zhong-jie Li, Hui-qi Dai, **ao-wei Huang, Ji Feng… in Acta Pharmacologica Sinica (2021)

  3. No Access

    Article

    ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma

    Sorafenib is the first-line treatment of advanced hepatocellular carcinoma (HCC). However, there is a lack of validated biomarkers to predict sorafenib sensitivity. In this study we investigated the role of AC...

    Ji Feng, Pei-zhi Lu, Guang-zhi Zhu, Shing Chung Hooi, Yong Wu… in Acta Pharmacologica Sinica (2021)